The safety of calcineurin inhibitors for kidney-transplant patients

Bibliography

• Oeconomos N, Hamburger J, Delinotte P, et al. Attempt at renal homograft (maternal kidney) after nephrectomy for traumatism of a lone kidney. Mem Acad Chir (Paris) 1953;79(25-6):642-52
   PubMedGoogle Scholar
• Murray JE, Merrill JP, Harrison JH. Renal homotransplantation in identical twins 1955. J Am Soc Nephrol 2001;12(1):201-4
   PubMed Web of Science ®Google Scholar
• Haesslein HC, Pierce JC, Lee HM, Hume DM. Leukopenia and azathioprine management in renal homotransplantation. Surgery 1972;71(4):598-604
   PubMed Web of Science ®Google Scholar
• Starzl TE, Groth CG, Brettschneider L. The use of heterologous antilymphocyte globulin (ALG) in human renal and liver transplantation. Int Congr Ser 1967;162:83-90
   PubMedGoogle Scholar
• Cohen DJ, Loertscher R, Rubin MF, et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984;101(5):667-82
   PubMed Web of Science ®Google Scholar
• Macleod AM, Thomson AW. FK 506: an immunosuppressant for the 1990s? Lancet 1991;337(8732):25-7
   PubMed Web of Science ®Google Scholar
• Rush D. The impact of calcineurin inhibitors on graft survival. Transplant Rev 2013;27:93-5
   Google Scholar
• Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508
   PubMed Web of Science ®Google Scholar
• Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity : a review and perspective of the evidence. Am J Nephrol 2013;37:602-12
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562-75
   PubMed Web of Science ®Google Scholar
• Morelon E, Mamzer-Bruneel MF, Peraldi MN, Kreis H. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant 2001;16(1):18-20
   PubMed Web of Science ®Google Scholar
• Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010;30(10):1044-56
   PubMed Web of Science ®Google Scholar
• Tedesco Silva HJr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010;10(6):1401-13
   PubMed Web of Science ®Google Scholar
• Cibrik D, Silva HTJr, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013;95(7):933-42
   PubMed Web of Science ®Google Scholar
• Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011;11(11):2453-62
   PubMedGoogle Scholar
• Moscarelli L, Caroti L, Antognoli G, et al. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience. Clin Transplant 2013;27(4):546-54
   PubMed Web of Science ®Google Scholar
• Chopra B, Sureshkumar KK. Co-stimulatory blockade with belatacept in kidney transplantation. Expert Opin Biol Ther 2014;14(5):563-7
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012;12(1):210-17
   PubMed Web of Science ®Google Scholar
• Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10(3):547-57
   PubMed Web of Science ®Google Scholar
• Vincenti F, Grinyó J, Rostaing L, et al. Belatacept-treated patients had better graft survival at 7-years post-transplant compared with cyclosporine-treated patients: final results from BENEFIT. Am J Transplant 2015;15(S3):abstract 452
   Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10(3):535-46
   PubMed Web of Science ®Google Scholar
• Martin ST, Powell JT, Patel M, Tsapepas D. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. Am J Health Syst Pharm 2013;70(22):1977-83
   PubMed Web of Science ®Google Scholar
• Kung L, Batiuk TD, Palomo-Pinon S, et al. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant 2001;1:325-33
   PubMed Web of Science ®Google Scholar
• Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979;2(8151):1033-6
   PubMed Web of Science ®Google Scholar
• The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983;309:809-15
   PubMed Web of Science ®Google Scholar
• The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at 3 years. N Engl J Med 1986;314:1219-25
   PubMed Web of Science ®Google Scholar
• Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;19:CD003961
   Google Scholar
• Busque S, Cantarovich M, Mulgaonkar S, et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant 2011;11(12):2675-84
   PubMed Web of Science ®Google Scholar
• Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40
   PubMed Web of Science ®Google Scholar
• Takahashi N, Hayano T, Suzuki M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989;337:473-5
   PubMed Web of Science ®Google Scholar
• Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989;341:758-60
   PubMed Web of Science ®Google Scholar
• Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991;352:803-7
   PubMed Web of Science ®Google Scholar
• Dieperink H, Starklint H, Leyssac PP, Kemp E. Glomerulotubular function in cyclosporine-treated rats. A lithium clearance, occlusion time/transit time and micropuncture study. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:853-9
   PubMedGoogle Scholar
• Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985;28:767-74
   PubMed Web of Science ®Google Scholar
• Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: A role of aldosterone. Am J Physiol Renal Physiol 2007;293:F2-9
   PubMed Web of Science ®Google Scholar
• Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998;49:356-63
   PubMed Web of Science ®Google Scholar
• Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci USA 1985;82:8222-6
   PubMed Web of Science ®Google Scholar
• Elzinga LW, Rosen S, Burdmann EA, et al. The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy. Transplantation 2000;69:2149-53
   PubMed Web of Science ®Google Scholar
• Lin CC, King KL, Chao YW, et al. Tacrolimus-associated hemolytic uremic syndrome: A case analysis. J Nephrol 2003;16:580-5
   PubMed Web of Science ®Google Scholar
• Bren A, Pajek J, Grego K, et al. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc 2005;37:1889-91
   PubMed Web of Science ®Google Scholar
• Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol 2007;67:335-40
   PubMed Web of Science ®Google Scholar
• Fernando M, Peake PW, Endre ZH. Biomarkers of calcineurin inhibitor nephrotoxicity in transplantation. Biomark Med 2014;8(10):1247-62
   PubMed Web of Science ®Google Scholar
• Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: The Achilles’ heel of immunosuppressive therapy. Kidney Int 1996;50:1089-100
   PubMed Web of Science ®Google Scholar
• Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984;311:699-705
   PubMed Web of Science ®Google Scholar
• Palestine AG, Austin HAIII, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986;314:1293-8
   PubMed Web of Science ®Google Scholar
• Randhawa PS, Shapiro R, Jordan ML, et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993;17:60-8
   PubMed Web of Science ®Google Scholar
• Morozumi K, Takeda A, Uchida K, Mihatsch MJ. Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? Transpl Proc 2004;36:S251-6
   PubMed Web of Science ®Google Scholar
• Nankivell B, Richard J, Borrows R, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33
   PubMedGoogle Scholar
• El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009;9:527-35
   PubMed Web of Science ®Google Scholar
• Wolf G, Killen PD, Neilson EG. Cyclosporin A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. J Am Soc Nephrol 1990;1:918-22
   PubMed Web of Science ®Google Scholar
• Khanna A, Plummer M, Bromberek C, et al. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002;62:2257-63
   PubMed Web of Science ®Google Scholar
• Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006;17:881-8
   PubMed Web of Science ®Google Scholar
• Vieira JMJr, Noronha IL, Malheiros DM, Burdmann EA. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation 1999;68:1746-53
   PubMed Web of Science ®Google Scholar
• Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine A-induced renal fibrosis: A role for epithelial-mesenchymal transition. Am J Pathol 2005;167:395-407
   PubMed Web of Science ®Google Scholar
• Hertig A, Verine J, Mougenot B, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006;6:2937-46
   PubMed Web of Science ®Google Scholar
• Rostaing L, Hertig A, Albano L, et al. Fibrosis Progression According to Epithelial-Mesenchymal Transition Profile: A Randomized Trial of Everolimus Versus CsA. Am J Transplant 2015;15(5):1303-12
   PubMed Web of Science ®Google Scholar
• Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997;52:660-73
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Imam F, Al-Harbi MM, et al. Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue. Biomed Res Int 2014;2014:607246
   Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung C L-S, et al. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004;78:461-8
   PubMed Web of Science ®Google Scholar
• Heering P, Grabensee B. Influence of ciclosporin A on renal tubular function after kidney transplantation. Nephron 1991;59:66-70
   PubMedGoogle Scholar
• Heering P, Ivens K, Aker S, Grabensee B. Distal tubular acidosis induced by FK506. Clin Transplant 1998;12:465-71
   PubMed Web of Science ®Google Scholar
• Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000;11:974-9
   PubMed Web of Science ®Google Scholar
• Alexander RT, Hoenderop JG, Bindels RJ. Molecular determinants of magnesium homeostasis: Insights from human disease. J Am Soc Nephrol 2008;19:1451-8
   PubMed Web of Science ®Google Scholar
• Greenberg A, Egel JW, Thompson ME, et al. Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant recipients. Am J Kidney Dis 1987;9:12-22
   PubMed Web of Science ®Google Scholar
• Solez K, Vincenti F, Filo R. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus ciclosporine. Transplantation 1998;66:1736-40
   PubMed Web of Science ®Google Scholar
• Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 2006;17:305-12
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377-86
   PubMed Web of Science ®Google Scholar
• Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status. Am J Transplant 2005;5:1111-19
   PubMed Web of Science ®Google Scholar
• Canales M, Youssef P, Spong R, et al. Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am J Transplant 2006;6:2157-63
   PubMed Web of Science ®Google Scholar
• Opelz G, Döhler B; Collaborative Transplant Study Transplantation. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009;87(6):795-802
   PubMed Web of Science ®Google Scholar
• Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810
   PubMed Web of Science ®Google Scholar
• Shihab FS, Waid TH, Conti DJ, et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. Transplantation 2008;85:1261-9
   PubMed Web of Science ®Google Scholar
• Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009;9(8):1876-85
   PubMed Web of Science ®Google Scholar
• Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-14
   PubMed Web of Science ®Google Scholar
• Verghese PS, Dunn TB, Chinnakotla S, et al. Calcineurin inhibitors in HLA-identical living related donor kidney transplantation. Nephrol Dial Transplant 2014;29:209-18
   PubMed Web of Science ®Google Scholar
• Gijsen V, Madadi P, Dubé MP, et al. Tacrolimus-induced nephrotoxicity and genetic variability : a review. Ann Transplant 2012;17:111-21
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Gelder T, van Schaik RHN, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004;76:545-56
   PubMed Web of Science ®Google Scholar
• Maes BD, Lemahieu W, Kuypers D, et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002;2:989-92
   PubMed Web of Science ®Google Scholar
• Lemahieu W, Maes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005;5:1383-91
   PubMed Web of Science ®Google Scholar
• Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82:711-25
   PubMed Web of Science ®Google Scholar
• Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: Recent developments. Ther Drug Monit 2006;28:720-5
   PubMed Web of Science ®Google Scholar
• International Neoral Renal Transplantation Study Group: Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002;2:148-56
   PubMed Web of Science ®Google Scholar
• Nashan B, Bock A, Bosmans JL, et al. Use of Neoral C2 monitoring: A European consensus. Transplant Int 2005;18:768-78
   PubMed Web of Science ®Google Scholar
• Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12:388-99
   PubMed Web of Science ®Google Scholar
• Bray R, Gebel H, Townsend R, et al. Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT. Am J Transplant 2015;15(S3):abstract 458
   Google Scholar
• Kasiske BL, Israni AK, Snyder JJ, Skeans MA. The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis 2011;57(3):466-75
   PubMed Web of Science ®Google Scholar
• Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005;18(1):22-8
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006;70:1019-25
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: Three-year analysis. Transplantation 2006;81:845-52
   PubMed Web of Science ®Google Scholar
• Lloberas N, Torras J, Alperovich G, et al. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant 2008;23:3111-19
   PubMed Web of Science ®Google Scholar
• Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011;79:897-907
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011;11:1665-75
   PubMed Web of Science ®Google Scholar
• Patel SJ, Elliott EN, Knight RJ, et al. Considerations in sirolimus use in the early and late post-transplant periods. Expert Opin Drug Saf 2009;8(4):421-34
   PubMed Web of Science ®Google Scholar
• Srinivas TR, Flechner SM, Poggio ED, et al. Glomerular filtration rate slopes have significantly improved among renal transplants in the United States. Transplantation 2010;90:1499-505
   PubMed Web of Science ®Google Scholar
• Heilman RL, Cortese C, Geiger XJ, et al. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. Transplantation 2012;93:47-53
   PubMed Web of Science ®Google Scholar
• Vítko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004;78(10):1532-40
   PubMed Web of Science ®Google Scholar
• Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004;4(4):626-35
   PubMed Web of Science ®Google Scholar
• Wiseman AC, McCague K, Kim Y, et al. The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. Am J Transplant 2013;13(2):442-9
   PubMed Web of Science ®Google Scholar
• Langer RM, Hené R, Vitko S, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int 2012;25(5):592-602
   PubMed Web of Science ®Google Scholar
• Mjörnstedt L, Sørensen SS, von Zur Mühlen B, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 2012;12(10):2744-53
   PubMed Web of Science ®Google Scholar
• Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012;12(5):1192-8
   PubMed Web of Science ®Google Scholar
• Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant 2015;15(1):119-28
   PubMed Web of Science ®Google Scholar
• Kamar N, Rostaing L, Cassuto E, et al. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipient. Clin Nephrol 2012;77(2):126-36
   PubMed Web of Science ®Google Scholar
• Kamar N, Del Bello A, Belliere J, Rostaing L. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation. Transpl Int 2015;28(8):928-37
   PubMed Web of Science ®Google Scholar
• Kamar N, Mariat C, Delahousse M, et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transplant 2007;22(7):1986-93
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3(2):178-85
   PubMed Web of Science ®Google Scholar
• Claes K, Meier-Kriesche HU, Schold JD, et al. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 2012;27(2):850-7
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011;91(9):976-83
   PubMed Web of Science ®Google Scholar
• Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008;21(2):146-51
   PubMed Web of Science ®Google Scholar
• Heit JJ. Calcineurin/NFAT signaling in the beta-cell: From diabetes to new therapeutics. Bioessays 2007;29(10):1011-21
   PubMed Web of Science ®Google Scholar
• Chen QJ, Li J, Zuo SR, et al. Tacrolimus decreases insulin sensitivity without reducing fasting insulin concentration: a 2-year follow-up study in kidney transplant recipients. Ren Fail 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991;18(3):353-8
   PubMed Web of Science ®Google Scholar
• Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012;12(3):630-9
   PubMed Web of Science ®Google Scholar
• Artz MA, Boots JM, Ligtenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003;14(7):1880-8
   PubMed Web of Science ®Google Scholar
• Dohgu S, Kataoka Y, Ikesue H, et al. Involvement of glial cells in cyclosporine-increased permeability of brain endothelial cells. Cell Mol Neurobiol 2000;20(6):781-6
   PubMed Web of Science ®Google Scholar
• Illsinger S, Janzen N, Lücke T, et al. Cyclosporine A: impact on mitochondrial function in endothelial cells. Clin Transplant 2011;25(4):584-93
   PubMed Web of Science ®Google Scholar
• Anghel D, Tanasescu R, Campeanu A, et al. Neurotoxicity of immunosuppressive therapies in organ transplantation. Maedica (Buchar) 2013;8(2):170-5
   PubMedGoogle Scholar
• Besenski N, Rumboldt Z, Emovon O, et al. Brain MR imaging abnormalities in kidney transplant recipients. AJNR Am J Neuroradiol 2005;26(9):2282-9
   PubMed Web of Science ®Google Scholar
• Rosario AM, Young JB. Interactive Grand Rounds. Case 3: management of cyclosporine-induced hirsutism and gingival overgrowth in a heart transplant recipient. J Heart Lung Transplant 2000;19(9):907-8
   PubMed Web of Science ®Google Scholar
• Hood KA. Drug-induced gingival hyperplasia in transplant recipients. Prog Transplant 2002;12(1):17-21; quiz 22-3
   PubMedGoogle Scholar
• Reali L, Zuliani E, Gabutti L, et al. Poor oral hygiene enhances gingival overgrowth caused by calcineurin inhibitors. J Clin Pharm Ther 2009;34(3):255-60
   PubMed Web of Science ®Google Scholar
• Rostaing L, Sánchez-Fructuoso A, Franco A, et al. Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. Transpl Int 2012;25(4):391-400
   PubMed Web of Science ®Google Scholar
• Tricot L, Lebbé C, Pillebout E, et al. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. Transplantation 2005;80(11):1546-9
   PubMed Web of Science ®Google Scholar
• Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338(24):1741-51
   PubMed Web of Science ®Google Scholar
• Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005;5(2):218-27
   PubMed Web of Science ®Google Scholar
• Lautenschlager I, Helanterä I, Inkinen K, et al. Effect of CMV Infection on Chronic Rejection of Kidney. In: Prösch S, Cinatl J, Scholz M, editors. New Aspects of CMV-Related Immunopathology. Monogr Virol. Karger; Basel: 2003. p. 10-22
   Google Scholar
• Leung Ki EL, Venetz JP, Meylan P, et al. Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. Clin Transplant 2008;22(2):245-9
   PubMed Web of Science ®Google Scholar
• Valenzuela M, Ortiz AM, Troncoso P, Vilches S. Strategies for prevention of cytomegalovirus infection in renal transplant patients. Transplant Proc 2009;41(6):2673-5
   PubMed Web of Science ®Google Scholar
• Bataille S, Moal V, Gaudart J, et al. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression. Transpl Infect Dis 2010;12(6):480-8
   PubMed Web of Science ®Google Scholar
• Havenith SH, Yong SL, van Donselaar-van der Pant KA, et al. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation 2013;95(1):184-91
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Vincenti F, Friman S, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 2013;13(1):136-45
   PubMed Web of Science ®Google Scholar
• Borni-Duval C, Caillard S, Olagne J, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation 2013;95(12):1498-505
   PubMed Web of Science ®Google Scholar
• Jacobi J, Prignitz A, Büttner M, et al. BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition. BMC Nephrol 2013;14:207
   PubMed Web of Science ®Google Scholar
• Deschler DG, Osorio R, Ascher NL, Lee KC. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. Arch Otolaryngol Head Neck Surg 1995;121(9):1037-41
   PubMed Web of Science ®Google Scholar
• Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003;75(7):987-93
   PubMed Web of Science ®Google Scholar
• Tiede C, Maecker-Kolhoff B, Klein C, et al. Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. Transplantation 2013;95(3):479-88
   PubMed Web of Science ®Google Scholar
• Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders. Cancer Treat Res 2015;165:305-27
   PubMedGoogle Scholar
• Martin ST, Powell JT, Patel M, Tsapepas D. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. Am J Health Syst Pharm 2013;70(22):1977-83
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Fraumeni JFJr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306(17):1891-901
   PubMed Web of Science ®Google Scholar
• Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397(6719):530-4
   PubMed Web of Science ®Google Scholar
• Kuschal C, Thoms KM, Schubert S, et al. Skincancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp Dermatol 2012;21(1):2-6
   PubMed Web of Science ®Google Scholar
• Thoms KM, Kuschal C, Oetjen E, et al. Cyclosporin A, but not everolimus, inhibits DNA repairmediated by calcineurin: implications for tumorigenesis under immunosuppression. Exp Dermatol 2011;20(3):232-6
   PubMed Web of Science ®Google Scholar
• Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporine regimens. Lancet 1998;351(9103):623-8
   PubMed Web of Science ®Google Scholar
• Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplantation recipients. N Engl J Med 2005;352:1317-23
   PubMed Web of Science ®Google Scholar
• Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9
   PubMed Web of Science ®Google Scholar
• Uslu Gokceoglu A, Akman S, Koyun M, et al. Hyperuricemia in pediatric renal transplant recipients. Exp Clin Transplant 2013;11(6):489-93
   PubMed Web of Science ®Google Scholar
• Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005;80(10):1383-91
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 2001;61(13):1957-2016
   PubMed Web of Science ®Google Scholar
• Van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002;25(10):707-12
   PubMed Web of Science ®Google Scholar